Targeting genetic changes to treat skin cancer
Targeting epigenetic abnormalities to inhibit cutaneous squamous cell carcinoma
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-10705718
This study is looking at how long-term sun exposure affects your genes and may lead to skin cancer, and it hopes to find new ways to reverse these changes to help stop tumor growth, which could lead to better treatments for people with skin cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10705718 on ClinicalTrials.gov |
What this research studies
This research investigates how chronic exposure to ultraviolet (UV) radiation leads to changes in the way genes are expressed, contributing to the development of cutaneous squamous cell carcinoma (cSCC), a common type of skin cancer. The study aims to understand the specific epigenetic modifications that occur and how reversing these changes could inhibit tumor growth. Using advanced techniques like CRISPR-Cas9, researchers will focus on demethylating a key gene involved in tumor suppression to see if this can reactivate its protective functions against cancer. Patients may benefit from new treatment strategies that target these epigenetic alterations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cutaneous squamous cell carcinoma or those at high risk due to chronic UV exposure.
Not a fit: Patients with other types of skin cancer or those not affected by UV exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that effectively inhibit the growth of skin cancer.
How similar studies have performed: Other research has shown promise in targeting epigenetic changes in cancer, suggesting that this approach could be effective.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAWASUMI, MASAOKI — UNIVERSITY OF WASHINGTON
- Study coordinator: KAWASUMI, MASAOKI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer, Cancer Causing Agents